News for Edwards Lifesciences Corporation (EW)

PR NewswireGALWAY, Ireland and WASHINGTON, March 9, 2025 CRT 2025 Late Breaking Science features largest head-to-head randomized control TAVR trial to prim

Looking into the current session, Edwards Lifesciences Inc. EW shares are trading at $71.65, after a 0.28% spike. Moreover, over the past month, the stock spike...

Edwards Lifesciences Corporation (NYSE: EW) today announced it will participate in the TD Cowen 45th Annual Health Care Conference on Tuesday, Mar. 4, 2025.

EW stock is on investors' radars due to the promising structural heart opportunities following the divestment of the Critical Care arm.

Earnings Call Insights: Edwards Lifesciences Corporation (NYSE:EW) Q4 2024Management ViewCEO Bernard Zovighian highlighted a strong Q4 2024 performance with...

Edwards Lifesciences Corporation (NYSE:EW) Q4 2024 Earnings Conference Call February 11, 2025 5:00 PM ETCompany ParticipantsMark Wilterding - Senior Vice...

Although the revenue and EPS for Edwards Lifesciences (EW) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Stocks Analysis by Christine Short covering: S&P 500, Microsoft Corporation, McDonald’s Corporation, Gilead Sciences Inc. Read Christine Short's latest article on Investing.com

Besides Wall Street's top -and-bottom-line estimates for Edwards Lifesciences (EW), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2024.

Stock Market today | Share Market Live Updates - Find here all the live updates related to Sensex, Nifty, BSE, NSE, share prices and Indian stock markets for 4 February 2025.

Edwards Lifesciences shares rise as analyst upgrades stock, citing TAVR growth, margin expansion, and strategic business changes for 2025.

Edwards Lifesciences (NYSE: EW) stock rises after Stifel upgrades to Buy, citing potential for TAVR growth acceleration in 2025. Read more here.

Favorable hospitalization trend, strong adoption of transcatheter heart valves and improved procedural volume are expected to have aided EW in the fourth quarter.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

This medtech giant is leveraging the power of artificial intelligence for a strong growth outlook.

High-rolling investors have positioned themselves bullish on Edwards Lifesciences EW, and it's important for retail traders to take note. \This activity came to...

Edwards Lifesciences (EW) stock faces a downgrade at Wolfe due to concerns over its TAVR market prospects. Read more here.

Wedgewood Partners, an investment management company, released its fourth-quarter 2024 investor letter. A copy of the letter can be downloaded here.